SOURCE-LINKED STUDY SUMMARY
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
Abstract summarizedQuality not appraised
- What was studied
- Narrative review integrating metabolic, inflammatory, immune and antifibrotic treatment targets for non-alcoholic steatohepatitis and fibrosis.
- Who / model studied
- The abstract describes pathways and candidate therapies rather than a defined participant group, species, sample size, intervention, comparator or follow-up period.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The review maps hormonal agonists, immune targets and stellate-cell pathways onto inflammation and fibrosis. It notes that fibrosis is reversible, but does not report a tested treatment effect.
- Limitations & context
- This is a mechanistic review, not a comparative clinical trial. The authors identify disease heterogeneity and divergent drivers as obstacles to finding broadly effective treatments; no author-stated methodological limitation appears in the abstract.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.jhep.2023.03.038